<DOC>
	<DOC>NCT00097812</DOC>
	<brief_summary>The purpose of this study is to assess bone mineral density in patients switching from an oral bisphosphonate to zoledronic acid, compared to those staying on the oral bisphosphonate.</brief_summary>
	<brief_title>Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Postmenopausal women between 45 and 79 years of age Must be osteopenic/osteoporotic Treatment with oral bisphosphonate for at least 1 year Any woman of child bearing potential Treatment with other bone active agents Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>osteoporosis, osteopenia, post-menopausal, zoledronic acid</keyword>
</DOC>